Aspect Partners’s Biogen BIIB Stock Holding History

Aspect Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-9	Closed	-$1.75K	–	602
2024 Q3	$1.75K	Hold	9	–	–	﹤0.01%	452
2024 Q2	$2.09K	Hold	9	–	–	﹤0.01%	460
2024 Q1	$1.94K	Hold	9	–	–	﹤0.01%	453
2023 Q4	$2.33K	Buy	+9	New	+$2.21K	﹤0.01%	424

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aspect Partners's BIIB Position: Q4 2024 in Review

Aspect Partners sold out of Biogen (BIIB) in Q4 2024, closing a stake of 9 shares — an estimated $1.75K sold.

Aspect Partners first reported a position in BIIB in Q4 2023 and held it in 4 quarters. The position peaked at $2.33K in Q4 2023. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

Aspect Partners reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
Aspect Partners sold 9 Biogen shares in Q4 2024, an estimated $1.75K.
Aspect Partners first reported a position in Biogen in Q4 2023 and held it in 4 quarters.
Aspect Partners's Biogen position peaked at $2.33K in Q4 2023.
876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Aspect Partners's 13F filing for Q4 2024, filed 3 Feb 2025.